

# BLMK AREA PRESCRIBING COMMITTEE (APC) ANNUAL REPORT

## April 2021 to March 2022



**“To promote rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes in order to ensure equity of access to medicines for all residents.”**

The following organisations contribute to and participate in the BLMK APC – Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group; Bedfordshire Hospitals NHS Foundation Trust; Cambridgeshire Community Services NHS Trust; Central and North West London NHS Foundation Trust; East London NHS Foundation Trust; Milton Keynes University Hospital NHS Foundation Trust



## **BLMK AREA PRESCRIBING COMMITTEE (APC) ANNUAL REPORT April 2021 to March 2022**

### **Introduction**

As a result of the CCG merger, the previous Bedfordshire and Luton Joint Prescribing Committee (JPC) and Milton Keynes Prescribing Advisory Group (MKPAG) have been replaced with the BLMK wide Area Prescribing Committee (BLMK APC). This is the first Annual Report of the BLMK APC, and the contents reflect the output from the committee meetings on 29<sup>th</sup> September 2021, 1<sup>st</sup> December 2021 and 2<sup>nd</sup> March 2022.

(NB. Due to Covid 19 staffing constraints, the 2<sup>nd</sup> March 2022 meeting was a combined meeting of the BLMK APC and the BLMK Formulary Subgroup.)

At this stage in the report, it is important that we acknowledge the work done by both legacy committees and the commitment of members to setting up and making the new committee work effectively under the new chair.

Output from the JPC meeting held 23<sup>rd</sup> June 2021 and the MKPAG meetings held 26<sup>th</sup> May 2021 and 28<sup>th</sup> July 2021 can be found in (Appendices 1 and 2) respectively.

The BLMK APC is a strategic local decision-making group with responsibility to promote rational, evidence-based, high quality, cost-effective medicines optimisation across Bedfordshire, Luton and Milton Keynes in order to ensure equity of access to medicines for all residents.

The APC makes decisions in ways that are clear, consistent and defensible and take account of regional and national recommendations using an explicit ethical framework and decision-making criteria that clinicians are aware of when submitting applications for clinical support and for funding.

There is a systematic approach to whole therapeutic areas, not looking solely at single medicines in isolation from the care pathway; there will be consideration of other health-system costs to support and facilitate service redesign.

The APC includes Medicines Safety and Antimicrobial Stewardship as standing agenda items.

The APC performs this work on behalf of the BLMK Clinical Commissioning Group (BLMK CCG) and its partnership organisations. The role of the APC includes discussion on BLMK wide implementation of national guidance on the use of medicines, such as NICE Technology Appraisals/Guidelines where medicines are included, assessment of the clinical and cost-effectiveness of medicines and medicines excluded from the National Tariff, discussion and agreement of local therapeutic guidelines where there is a large medicines component and assisting in the resolution of problems relating to prescribing at the primary and secondary care interface. The focus of the Committee has

changed in recent years. There has been a shift away from evaluation of new medicines to production of therapeutic guidelines/pathways to assist in safe, effective and cost-effective prescribing. This reflects the changing role of Area Prescribing Committees which now focuses more on production of medicine related guidelines

Please [click here](#) to access the current Terms of Reference of BLMK APC.

### **APC Subgroups**

Three subgroups to the APC have been created. All are advisory and make recommendations to the APC for ratification:

1. BLMK Formulary Group: There are currently two joint Formularies - Milton Keynes Joint Formulary and Bedfordshire and Luton Joint Formulary. The BLMK Formulary Group focusses on the evaluation of new medicines and additional preparations of existing medicines with potential impact in primary and secondary care (prescribing or commissioning) for addition to both Joint Formularies. It also reviews sections of the Formularies and prepares shared care guidelines. Acute Trust Drugs and Therapeutics Committees focus on reviewing hospital only drugs. Medicines which are the subject of a positive NICE Technology Appraisal Guidance are automatically added to both Joint Formularies. Please [click here](#) to access the current Terms of Reference of the Formulary Group. While formal merger of the two Joint Formularies is not anticipated in the short term. In the longer term, alignment of the Formularies is anticipated as a result the work of the BLMK Formulary Subgroup.
2. The newly formed BLMK Medicines Safety Group (MSG) provides information on medicines safety drug updates (DSU) and patient safety alerts to the APC. The MSG is a forum to inform and improve medication safety across the BLMK health economy sharing of information about and learning from medication safety issues occurring in both primary and secondary care. It also makes medicines safety recommendations which span the interface between primary and secondary care. Please [click here](#) to access the current Terms of Reference of the BLMK Medicines Safety
3. Wound Management Formulary Steering Group. The purpose of the Wound Management Formulary Steering Group is: To provide strategic oversight in all aspects of Wound Management products across the local health economy in Bedfordshire, Luton and Milton Keynes (BLMK). To develop, implement, and monitor the application of wound management documentation, policies, guidance and practice. This group has been in existence for many years serving Bedfordshire and Luton and has been extended to include representation from Milton

Keynes. Please [click here](#) to access the current Terms of Reference of the Wound Management Formulary Steering Group.

The APC and its subgroups work to their terms of reference, and follow an Ethical and Commissioning Principles framework, incorporating an Equality and Diversity Impact Assessment where applicable (Appendix 3) when producing recommendations on medicines/guidelines. APC and Subgroup members are asked to complete the current [declarations of conflict of interest](#) and do not take part in decision-making where a conflict of interest arises.

### **Participating Organisations:-**

The APC serves the following participating NHS organisations:

- Bedfordshire Hospitals NHS Foundation Trust (Bedford site and Luton & Dunstable site)
- Milton Keynes Hospital University Hospital NHS Foundation Trust
- East London Foundation NHS Trust (ELFT) (Provides Mental Health Services to Bedfordshire and Luton and Community Health Services to Bedfordshire).
- Cambridgeshire Community Services NHS Trust (Provides Community Health Services to Luton).
- Central and North West London NHS Foundation Trust (CNWL) (Provides Community and Mental Health Services to Milton Keynes).
- BLMK Clinical Commissioning Group.

Representation on the APC comes from the participating organisations and is included in the APC Terms of Reference. The Committee chair is a Non-Executive Director of BLMK CCG.

### **Meeting Attendance Figures**

APC meetings are usually held bi-monthly and the Committee first met in September 2021. There has been a total of three business APC committee meetings held from September 2021 to March 2022. Meetings were held virtually by Microsoft Teams and at dates and times that members have said they would be available. Dates and times of meetings are set at least 6 months in advance of the meeting. The table below illustrates APC member and participating NHS organisations APC attendance from September 2021 to March 2022 for the three business meetings. (Some members deputise for each other and % attendance reflects this fact.). NB the March meeting was a joint meeting with the Formulary Subgroup, and this affects the attendance as some of the members outlined below do not normally attend the APC.\* People who attend in 'an attendance capacity' are not included in the table.

Job Title	Organisation representing	2021/22 % attendance
Chair	Working on behalf of the Committee	100%
Place Based Lead GP– Milton Keynes	BLMK CCG	0%
Place Based Lead GP– Milton Keynes Deputy	BLMK CCG	33%
Place Based Lead GP – Luton	BLMK CCG	100%
Place Based Lead GP – Central Bedfordshire	Place Based Lead GP	66%
Place Based Lead GP – Bedford	BLMK CCG	100%
Place Based Lead GP – Bedford Deputy	BLMK CCG	0%
Pharmacist Representative	Bedfordshire Hospitals NHS Foundation Trust	100%
Pharmacist Representative - Deputy	Bedfordshire Hospitals NHS Foundation Trust	50%
Pharmacist Representative	Milton Keynes University Hospital NHS Foundation Trust	100%
Pharmacist Representative - Deputy	Milton Keynes University Hospital NHS Foundation Trust	100%
Consultant in Public Health	Working on behalf of the Committee	100%
Medical Representative	Bedfordshire Hospitals NHS Foundation Trust	66%
Medical Representative – Deputy	Bedfordshire Hospitals NHS Foundation Trust	100%
Medical Representation	Milton Keynes University Hospital NHS Foundation Trust	66%
Medical Representative – Deputy	Milton Keynes University Hospital NHS Foundation Trust	33%
APC Professional Secretary	Working on behalf of the Committee	100%
Pharmacist Representative	Assisting the Professional Secretary working on behalf of the Committee	66%
Lay Representative	Working on behalf of the Committee	100%
Associate Director and Head of Medicines Optimisation	BLMK CCG	100%
Place Based Lead Pharmacist – Central Bedfordshire	BLMK CCG	100%
Place Based Lead Pharmacist – Bedford	BLMK CCG	100%
Place Based Lead Pharmacist – Luton	BLMK CCG	100%
Interim Integrated Care System (ICS) Chief Pharmacist	BLMK CCG	66%
Chair of Medicines Safety Group	Secondary Care	100%
Chair of Wound Care Group	BLMK CCG	100%
Chair of Formulary Subgroup	BLMK CCG	100%
Formulary Lead Pharmacist	BLMK CCG	66%

Formulary Lead Pharmacy Technician	BLMK CCG	100%
Nurse and Non-Medical Prescribing Representative	Secondary Care	66%
Pharmacist Representative	CNWL (Community and Mental Health Services Milton Keynes)	66%
Pharmacist Representative	ELFT (Community Services (Beds)/Mental Health Services (Beds and Luton))	100%
Pharmacist Representative	CCS (Beds & Luton Community Services Provider)	100%
Community Pharmacist Representative	Community Pharmacy	33%*

In addition to those outlined above, the Committee also welcomed the attendance and contribution of other colleagues from participating organisations, including observers who attended as part of their non-medical prescribing course.

## Committee's Activities and Achievements

### • Communication and consultation

Key stakeholders are identified and consulted when medicines/pathways within specialist areas are discussed. As many views as possible are sought and considered during the APC meeting. Specialists/staff with specialist input are invited to attend APC meetings to contribute to the meeting or make presentations. A total of 10 presentations were made over the three business meetings held from September 2021 to March 2022.

In addition, where complex guidelines are discussed, clinicians are invited to participate in subgroup meetings prior to full discussion at APC.

A consensus recommendation is reached by APC members, and these are presented in the form of APC recommendations and more detailed APC Guidelines which are communicated to key stakeholders either individually (via email) or through newsletters.

The APC and its Subgroups have produced a variety of guidance on the appropriate and cost-effective use of medicines during the 2021/22 financial year and these are outlined below.

### • Guidelines, Pathways and Bulletins

The following Guidelines, Pathways and Bulletins were produced or updated and ratified during the 2021/22 Financial Year:-

- Strategies to support reduced inhaler carbon emissions
- Antimicrobial prescribing guidelines for primary care (BLMK) – update and alignment
- Interim BLMK Primary Care Guidelines for management of chronic non-cancer pain in adults
- Bariatric Surgery – Vitamins and minerals
- Oxygen for cluster headaches

- Primary Care Guideline for Adults with Asthma Update
- Treatment Pathway for Active psoriatic Arthritis
- Ankylosing Spondylitis – Biologics Treatment Pathway for Ankylosing Spondylitis for Non-radiographic Axial Spondyloarthritis (nrAxial SpA)
- Treatment Pathway for Rheumatoid Arthritis Update
- Severe Psoriasis Pathway
- Inclisiran for Primary hypercholesterolaemia or mixed dyslipidaemia
- Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD (Update)
- Dry Eye Guidance – BLMK alignment
- Testosterone Gel Fact Sheet - Menopause

Copies of the Guidelines, Pathways and Bulletins are available on the [BLMK Medicines Optimisation website](#) with Formulary specific information available by accessing the two joint formularies:-

<http://www.bedsformulary.nhs.uk/>

<https://formularymk.nhs.uk/>

- **Shared care guidelines/Information for GPs**

During 2021/2022 the following shared care guidelines/information for GPs were produced/ updated and ratified:-

- Transgender Shared Care Guidelines - Updates
- Cinacalcet for the treatment of primary Hyperparathyroidism in patients awaiting surgery or deemed unfit for surgical management
- Denosumab (Prolia®) for the Treatment of Osteoporosis in Post-Menopausal Women and Adult Males ( $\geq 50$  years) at Increased Risk of Fractures
- ADHD Shared Care Guideline for Adults

These are available on the BLMK Medicines Management website (<https://medicines.blmkccg.nhs.uk/categories/shared-care-guidelines/>) along with previously produced shared cared guidelines for practitioners to access when needed.

- **Miscellaneous Documents**

The following miscellaneous documents were approved or noted (for information) by the APC Committee during September 2021 to March 22:-

- Shared Care Guideline Template
- BLMK APC Terms of Reference
- Formulary Subgroup Terms of Reference
- Medicines Safety Group Terms of Reference

- Bedfordshire, Luton and Milton Keynes Wound Management Formulary Steering Group Terms of Reference
- Updated paperwork for use by the BLMK APC and Formulary Subgroup
- Minutes of meetings from the contributing organisations to the APC
- New treatments for COVID-19
- Blood glucose and steroid therapy in palliative care patients – ELFT
- Dapagliflozin and Type 1 Diabetes – licence change
  
- Perinatal Mental Health Prescribing Document - Approved by BLMK Prescribing Committee (Feb 2022)

This information can be found on the BLMK Medicines Management website (<https://medicines.blmkccg.nhs.uk/> ) and via the Joint Formularies (Formulary specific information) - <http://www.bedsformulary.nhs.uk/> <https://formularymk.nhs.uk/>

- **NICE Guidance**

NICE Technology Appraisal Guidance (NICE TAs) and guidelines were noted by the BLMK APC from September 2021 to March 2022. NICE TAs which are the commissioning responsibility of CCGs are noted for implementation. NICE Guidelines are noted for information and action where appropriate and NICE TAs where the commissioning responsibility rests with NHS England (NHSE) are noted for information only. As a result of the issue of NICE Guidance, updates to existing APC guidance and BLMK Formulary are undertaken.

See appendix 4 for information on CCG Commissioned NICE Technology Appraisal Guidance considered by the APC between September 2021 and March 2022.

**[Click here](#) to access all NICE Guidance issued from 17<sup>th</sup> June 2021 to 16<sup>th</sup> February 2022.**

The APC also received reports from its Subgroups and ratified recommendations made at these groups:-

- **BLMK Wound Management Formulary Steering Group.**

The APC ratifies the formulary recommendations of the BLMK Wound Care Formulary Steering Group which has representation from relevant clinicians across Bedfordshire, Luton and Milton Keynes.

Currently there are two Formularies in operation. The Bedfordshire and Luton Wound Care Formulary can be accessed by clicking on the following link: <https://medicines.blmkccg.nhs.uk/categories/formulary/>

The Milton Keynes Wound Care Formulary for Practice Nurses and Nursing Homes is made available through a system called NWOS: [NWOS Surgical](https://www.nwossurgical.co.uk/) <https://www.nwossurgical.co.uk/>

Details of additions and deletions made to the Wound Care Formulary between September 2021 and March 2022 can be accessed from the September 2021, November 2021 and March 2022 Formulary Newsletters:- <https://medicines.blmkccg.nhs.uk/>

- **BLMK Formulary Group**

The Formulary additions and deletions made between September 2021 and March 2022 can be accessed from the September 2021, November 2021 and March 2022 Formulary Newsletters:-

<https://medicines.blmkccg.nhs.uk/>

The BLMK Formularies can be accessed by clicking on the following links:

<http://www.bedsformulary.nhs.uk/>

<https://formularymk.nhs.uk/>

- **BLMK Medicines Safety Group (MSG)**

The BLMK Medicines Safety group brought the Drug Safety Updates and national Patient Safety Alerts to the APC for information and action. This information can be accessed from the September 2021, December 2021 and March 2022 APC Newsletters <https://medicines.blmkccg.nhs.uk/>

- **Antimicrobial Resistance Update**

Updates are provided to the Committee by the BLMK CCG Lead Antimicrobial Pharmacist, and the information provided can be accessed from the September 2021, December 2021 and March 2022 APC Newsletters <https://medicines.blmkccg.nhs.uk/>.

- **East of England Priorities Advisory Committee (EoE PAC)**

Bulletins produced by the APC have been submitted to the EoE PAC to help inform production of East of England wide policies on medicines where it is appropriate to have these. Outputs from EoE PAC are considered and ratified by the APC as appropriate.

The APC ratified the following EoEPAC recommendations and bulletins between September 2021 and March 2022:-

- [Thuasne ActionReliever® Off-loading Knee Brace for Osteoarthritis Bulletin and Recommendations](#)

- Localised Severe Psoriasis Guidance (Interim)

- **Regional Medicines Optimisation Committees (RMOCs)**

The output from RMOCs is included as a standing agenda item on the APC and are actioned as appropriate.

- **APC Newsletter**

An APC Newsletter is produced following each Business meeting of the Committee providing a brief summary of APC recommendations and is widely circulated within the Bedfordshire, Luton and Milton Keynes health economy (GPs, Community Pharmacists, and Secondary Care). Three Newsletters have been produced from September 2021 to March 2022 and can be accessed from:- <https://medicines.blmkccg.nhs.uk/>

- **Future Work Programme**

The work plan of the new APC includes updating, aligning and/or developing new pathways/guidelines including the following:-

- Migraine Pathway
- Vitamin D Pathway Update
- COPD Guideline Update
- SGLT2 Inhibitors for CKD
- Dermatology Pathway Update
- Continuous Glucose Monitoring Pathway and Product choice
- Ulcerative Colitis Pathway
- Crohn's Disease Pathway Update
- Osteoporosis Guideline Update
- Ophthalmology Pathway Update

## **Summary**

The BLMK Area Prescribing Committee has, during the 2021/22 financial year, continued to build on the legacy of its predecessor committees to ensure the provision of recommendations on the safe, clinical and cost-effective use of medicines to the BLMK CCG and provider Trusts to improve patient outcomes of the Bedfordshire, Luton and Milton Keynes population. The meetings have been well attended with good representation from primary care, secondary care and lay members.

Finally, we hope you find this annual report helpful. Any comments on this document are welcomed by the APC Secretary.

### **APC Secretary contact details:**

E-mail: [anne.graeff@nhs.net](mailto:anne.graeff@nhs.net)  
Arndale House  
Luton

## Appendix 1

### **OUTPUT FROM THE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) HELD ON 23<sup>RD</sup> JUNE 2021**

The approved meeting notes, newsletter (summarising decisions made at the meeting) and Formulary Newsletter (to include agreed updates to the Bedfordshire and Luton Joint Formulary) can be accessed by clicking on the following links: -

[Bedfordshire and Luton Joint Prescribing Committee 23<sup>rd</sup> June 2021 Meeting Notes \(approved\)](#) and associated [Newsletter](#) and [Formulary Newsletter](#).

## Appendix 2

### **OUTPUT FROM THE MILTON KEYNES PRESCRIBING ADVISORY GROUP (MKPAG) MEETINGS HELD ON 26<sup>th</sup> MAY 2021 and 28<sup>th</sup> JULY 2021**

The approved meeting notes can be accessed from the following weblinks:-

[26<sup>th</sup> May 2021 Meeting Notes](#)

[28<sup>th</sup> July 2021 Meeting Notes](#)

## Appendix 3

**Bedfordshire, Luton and Milton Keynes Area Prescribing Committee (BLMK APC) Assessment against Ethical and Commissioning Principles**

<b>Treatment assessed (Month and Year):</b>
<b>BLMK APC Recommendation</b>
<b>1) Clinical Effectiveness</b>
<b>2) Cost Effectiveness</b>
<b>3) Equity &amp; Equality Impact Assessment*</b>
<p>Will this decision of the APC have an impact for patients or staff in regard to Equality, Inclusion and Human Rights legislation? Such impacts (negative) could include:</p> <ul style="list-style-type: none"> <li>• Restriction of a drug which could benefit those with certain conditions<sup>1,2</sup></li> </ul> <p><sup>1</sup>NB Equality and Diversity is only one part of an assessment of the new drug/indication. <sup>2</sup>It should be noted that where the Bedfordshire, Luton and Milton Keynes Area Prescribing Committee is following national guidance, these have been developed with consultation and are required to have been subject to Equality Analysis and Due Regard.</p>
<p><b>YES</b> If the proposal is likely to impact patients or staff, please set out those impacts and any mitigations that have been identified.</p> <p>Examples include a process where the needs of exceptional cases can be met.</p> <p><u>Should a significant impact be identified an EQIA should be completed</u></p>
<p>If <b>NO</b>, please state that the decision has been reviewed with regard to Equality, Inclusion and Human Rights and no issues have been identified.</p>
<b>4) Needs of the community</b>
<b>5) Need for healthcare (incorporates patient choice and exceptional need)</b>
<b>6) Policy drivers:</b>

**7) Disinvestment**

Where the implementation of the decision of the Bedfordshire, Luton and Milton Keynes Area Prescribing Committee may impact on one or more equality group differently to others, BLMK CCG will require a full equality impact assessment to be completed.

**Protected Characteristics (under the Equality Act):-**

Age; Disability; Gender reassignment; Marriage & Civil Partnership (in employment only); Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual orientation; carers; other identified groups.

## Appendix 4

**NICE Technology Appraisal Guidance (CCG Commissioned) –  
considered by BLMK APC September 2021 – March 2022**

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis  
Technology appraisal guidance [TA708] Published: 23 June 2021  
<https://www.nice.org.uk/guidance/ta708>

Guselkumab for treating active psoriatic arthritis after inadequate response to  
DMARDs, Technology appraisal  
guidance [TA711] Published: 30 June 2021  
<https://www.nice.org.uk/guidance/ta711>

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial  
fibrillation, Technology appraisal guidance [TA249] Published: 15 March 2012 Last  
updated: 02 July 2021. <https://www.nice.org.uk/guidance/ta249>

Rivaroxaban for the prevention of stroke and systemic embolism in people with  
atrial fibrillation, Technology appraisal guidance [TA256] Published: 23 May 2012  
Last updated: 02 July 2021. <https://www.nice.org.uk/guidance/ta256>

Apixaban for preventing stroke and systemic embolism in people with non-valvular  
atrial fibrillation, Technology appraisal guidance [TA275] Published: 27 February  
2013 Last updated: 02 July 2021. <https://www.nice.org.uk/guidance/ta275>

Edoxaban for preventing stroke and systemic embolism in people with non-valvular  
atrial fibrillation, Technology appraisal guidance [TA355] Published: 23 September  
2015 Last updated: 02 July 2021. <https://www.nice.org.uk/guidance/ta355>

Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid  
arthritis after conventional DMARDs have failed, Technology appraisal guidance  
[TA715] Published: 14 July 2021. <https://www.nice.org.uk/guidance/ta715>

Secukinumab for treating non-radiographic axial spondyloarthritis, Technology  
appraisal guidance  
[TA719] Published: 21 July 2021. <https://www.nice.org.uk/guidance/ta719>  
Ixekizumab for treating axial spondyloarthritis, Technology appraisal guidance  
[TA718] Published: 21 July 2021.  
<https://www.nice.org.uk/guidance/ta718>

Continuous positive airway pressure for the treatment of obstructive sleep  
apnoea/hypopnoea syndrome Technology appraisal guidance [TA139] Published:  
26 March 2008 Last updated: 20 August 2021.  
<https://www.nice.org.uk/guidance/ta139>

Bimekizumab for treating moderate to severe plaque psoriasis  
Technology appraisal guidance [TA723] Published: 01 September 2021  
<https://www.nice.org.uk/guidance/ta723>

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia,  
Technology appraisal guidance [TA733] Published: 06 October 2021,  
<https://www.nice.org.uk/guidance/ta733>

Upadacitinib for treating moderate rheumatoid arthritis, Technology appraisal guidance [TA744] Published: 10 November 2021,  
<https://www.nice.org.uk/guidance/ta744>

Cenobamate for treating focal onset seizures in epilepsy, Technology appraisal guidance [TA753] Published: 15 December 2021.  
<https://www.nice.org.uk/guidance/ta753>

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy, Technology appraisal guidance [TA758] Published: 05 January 2022  
<https://www.nice.org.uk/guidance/ta758>

Fostamatinib for treating refractory chronic immune thrombocytopenia, Technology appraisal guidance [TA759] Published: 07 January 2022  
<https://www.nice.org.uk/guidance/ta759>

Sodium zirconium cyclosilicate for treating hyperkalaemia, Technology appraisal guidance [TA599] Published: 04 September 2019 Last updated: 24 January 2022  
<https://www.nice.org.uk/guidance/ta599>

Fremanezumab for preventing migraine, Technology appraisal guidance [TA764] Published: 02 February 2022  
<https://www.nice.org.uk/guidance/ta764>

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs, Technology appraisal guidance [TA768] Published: 02 February 2022  
<https://www.nice.org.uk/guidance/ta768>

Palforzia for treating peanut allergy in children and young people, Technology appraisal guidance [TA769] Published: 02 February 2022  
<https://www.nice.org.uk/guidance/ta769>